Navigation Links
Scientist Discovers Crucial Part of Blood-Clotting Process

A researcher at The University of Texas Health Center at Tyler has discovered how a small but crucial part of the blood-clotting process works. Once the process// is thoroughly understood, synthetic chemicals can be designed to regulate it, thus preventing excessive bleeding or blood clotting. The findings of Pierre Neuenschwander, Ph.D., and his team are published in the Aug. 11, 2006, edition of the Journal of Biological Chemistry.

Dr. Neuenschwander, an associate professor of biochemistry, and his team are investigating one step in the blood-clotting process that involves factor IXa, an enzyme (IX and the other factors are read as Roman numerals). Enzymes are proteins that change the rate of chemical reactions without needing an external energy source, such as heat.

“If you don’t have factor IXa, you have hemophilia, or excessive bleeding, and your blood doesn’t clot properly. So you have to have factor IXa, but not too much of it. If it’s left unregulated, you get clots where you don’t want them and end up with strokes and heart attacks,” Dr. Neuenschwander said.

“It’s been difficult to study how factor IXa works. It’s not usually a very active enzyme. This research paper is one of the first to show that a physiologically relevant molecule, heparin, can modulate the activity of factor IXa,” he said. Heparin is a naturally occurring mixture of compounds that prevents unwanted blood clotting. It is a molecule with many places where enzymes and other substances can bind to activate or stop biochemical reactions in the cell.

By revealing how factor IXa works, it should be possible to make synthetic chemicals that prevent strokes and heart attacks, Dr. Neuenschwander said. Conversely, you could make synthetic activators that could stop the unwanted bleeding that occurs in hemophilia, he added.

Dr. Neuenschwander has been investigating factor IXa for the past six years. His first research was funded by a smal l grant from the American Heart Association. Currently, his research is funded by a five-year, $1.375 million grant from the National Institutes of Health that ends in 2010. The NIH grant originally was for just four years; the NIH thought enough of Dr. Neuenschwander’s research to award him another year of funding.

He and his team plan to spend the next year experimenting with antithrombin, a small naturally occurring molecule that inactivates several enzymes involved in the coagulation process. They hope to gain understanding of another step in that process.

“We want to see if we can design inhibitors that would mimic what heparin does. Our goal is to develop these and eventually test them in clinical trials,” Dr. Neuenschwander said.

(Source Newswise)

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:

(Date:10/13/2015)... ... 2015 , ... PhyMed Healthcare Group , a physician-led ... with WPC Healthcare , a provider of predictive analytics solutions for healthcare. ... an aggregated data repository necessary to perform reporting and analytics on selected quality ...
(Date:10/13/2015)... ... October 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich ... Cosmetic Symposium to be held March 2nd and 3rd, 2016. The annual meeting, along ... surgeons and cosmetic physicians from around the world. , Key topics at this year's ...
(Date:10/13/2015)... ... 2015 , ... e-con Systems Inc., a leading embedded design services company specializing ... first RGB-IR pixel format camera with a USB 3.0 interface and e-CAM40_CUMI4682_MOD, ... UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a 4-megapixel image ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ... and workflow solutions, announced today their Title Sponsorship of Synergy 2015. The annual ... Henderson, NV at Green Valley Ranch and will unite customers, partners, WennSoft team ...
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe ... and IV sedation dentistry for more than 5 years. A leading cause ... serious and painful if treatment is not timely. , Sedation dentistry ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Regen BioPharma, Inc. , (OTCBB: RGBP, ... , PhD as its new president.  Dr. Lander will work ... as Regen BioPharma prepares to take the next steps ... Regen BioPharma, Inc. , (OTCBB: RGBP, OTC: RGBP) ... as its new president.  Dr. Lander will work closely with ...
(Date:10/13/2015)... HANGZHOU, China , Oct. 13, 2015 ... (the "Company" or " China Jo-Jo "), a leading ... health care products through its own online and retail ... for the Company,s official branded online pharmacy through ... profit margin was a record 25%. ...
(Date:10/13/2015)... World Thrombosis Day Interactive Infographic ...   --> World Thrombosis Day Interactive ... promote vital global awareness of thrombosis, its causes, ... the formation of potentially deadly blood clots in ... thromboembolism (VTE) - or the artery (arterial thrombosis) [1] ...
Breaking Medicine Technology: